Specialty Pharmacy

What counts as a specialty drug

There is no single statutory definition. In practice a medication is handled as specialty when it combines several of: high cost, biologic or cell-derived manufacture, refrigerated or frozen storage, injection or infusion administration, a narrow therapeutic window, intensive monitoring, or a restricted distribution channel.

The therapeutic areas that dominate are oncology, immunology and rheumatology, multiple sclerosis, hepatitis and HIV, transplant, and rare or orphan disease.

Because payers define their own specialty drug lists, the same product can be handled as specialty under one benefit and as a standard prescription under another.

Accreditation and payer access

Specialty pharmacies commonly hold accreditation from URAC, ACHC, or both, and some also hold accreditation from The Joint Commission or NABP. Accreditation examines patient management, clinical protocols, dispensing accuracy, performance measurement and privacy practice.

Accreditation matters commercially as well as clinically: payers, pharmacy benefit managers and manufacturers frequently require it before admitting a pharmacy to a network or a distribution channel. Losing it can close access to whole categories of business.

Limited distribution and REMS

A manufacturer may restrict a product to a limited distribution network — a named set of pharmacies permitted to dispense it. Access is granted by the manufacturer, so a pharmacy outside the network cannot supply the drug at any price.

Separately, the FDA can require a Risk Evaluation and Mitigation Strategy (REMS) for a drug with a serious safety concern. A REMS can require prescriber and pharmacy certification, patient enrolment, documented counselling, laboratory monitoring before dispensing, or controlled distribution.

Both mechanisms add process the pharmacy has to run and evidence: enrolment, verification, documentation and reporting steps that sit between the prescription and the dispense.

What the work involves

A large part of specialty practice happens before the medication moves. Benefits investigation establishes how the drug is covered, prior authorisation gathers the clinical evidence the payer requires, and financial assistance work connects patients to manufacturer or foundation support where they qualify.

After dispensing, the pharmacy runs structured clinical follow-up — adherence and persistence monitoring, side-effect management, injection training, and refill coordination timed to therapy.

Cold chain handling is routine: validated packing, temperature monitoring in transit, and documented excursion procedures.

For pharmacists, the distinguishing experience is therapeutic depth in a specialty area plus fluency in prior authorisation and appeals. For technicians, it is benefits investigation, payer portals, enrolment paperwork and cold-chain shipping.